Home/Pipeline/Undisclosed TRACIr Program

Undisclosed TRACIr Program

Solid Tumors

PreclinicalResearch

Key Facts

Indication

Solid Tumors

Phase

Preclinical

Status

Research

Company

Janux Therapeutics

About Janux Therapeutics

Janux Therapeutics is pioneering a new class of tumor-activated immunotherapies designed to overcome the limitations of traditional T-cell engagers, particularly their severe on-target, off-tumor toxicities. The company's proprietary platforms conditionally activate only in the tumor microenvironment, aiming to unlock the potential of powerful immunotherapies for solid tumors. With its lead candidate JANX007 in Phase 1 clinical trials for metastatic castration-resistant prostate cancer and a strong pipeline of other candidates, Janux is positioned at the forefront of next-generation immuno-oncology. The company went public in 2021 and is backed by a seasoned leadership team with deep experience in oncology drug development.

View full company profile

Therapeutic Areas

Oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
GSK4362676	GSK plc	Phase 1	Active
ABBV-154	AbbVie	Phase 1	Active
TAK-981	Takeda Pharmaceutical	Phase 1/2	Active
TAK-676	Takeda Pharmaceutical	Phase 1	Active
TAK-573	Takeda Pharmaceutical	Phase 1	Active
TAK-164	Takeda Pharmaceutical	Phase 1	Active
SHR-1316	Jiangsu Hengrui Medicine	Phase 1/2	Active
BAY 2927088	Bayer	Phase 1	Active
ASP1929	Astellas Pharma	Phase 2	Active
IBI188	Innovent Biologics	Phase 1	Active
Bispecific Antibody	Akeso	Phase 1/2	Active
CSPC-DM02	CSPC Pharmaceutical Group Limited	Phase 2	Active